Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation

Cardiovascular Research

Volumn 107, Issue 4, 2015, Pages 568-578

  Stanley, Christopher P ^a   Hind, William H ^a   Tufarelli, Cristina ^a   O'Sullivan, Saoirse E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cannabidiol; Cannabinoid; Endothelium; Human; Vasorelaxation

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NITRIC OXIDE; PROTEIN KINASE B; S6 KINASE; STAT5 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; VASODILATOR AGENT;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; INTRACELLULAR SIGNALING; MALE; MESENTERIC ARTERY; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; VASODILATATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS; VASCULAR ENDOTHELIUM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CANNABIDIOL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MESENTERIC ARTERIES; MIDDLE AGED; MULTIPLE SCLEROSIS; NITRIC OXIDE; RECEPTOR, CANNABINOID, CB1; VASODILATION; VASODILATOR AGENTS;

EID: 84948176765     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv179     Document Type: Article

References (63)

1. Stanley C, OSullivan SE. Vascular targets for cannabinoids: animal and human studies. Br J Pharmacol 2014;171:1361-1378.
2. Montecucco F, Di Marzo V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 2012;33:331-340.
3. Schubart CD, Sommer IE, van GastelWA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011;130:216-221.
4. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-Tetrahydrocannabinol, cannabidiol and delta9-Tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215.
5. Stanley CP, Hind WH, OSullivan SE. Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol 2013;75:313-322.
6. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234-246.
7. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30:515-527.
8. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008;30:271-280.
9. Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 2009;15:65-75.
10. BoozGW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radical Bio Med 2011;51:1054-1061.
11. Rajesh M, Mukhopadhyay P, Batkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horvath B, Mukhopadhyay B, Becker L, Hasko G, Liaudet L, Wink DA, Veves A, Mechoulam R, Pacher P. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010;56:2115-2125.
12. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Drel VR, Obrosova IG, Pacher P. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 2007;293:H610-H619.
13. Ruiz-Valdepenas L, Martinez-Orgado JA, Benito C, Millan A, Tolon RM, Romero J. Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. J Neuroinflammation 2011;8:5.
14. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai N-T, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006;168:235-244.
15. Walsh SK, Hepburn CY, Kane KA, Wainwright CL. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br J Pharmacol 2010;160:1234-1242.
16. Hayakawa K, Mishima K, Irie K, Hazekawa M, Mishima S, Fujioka M, Orito K, Egashira N, Katsurabayashi S, Takasaki K, Iwasaki K, Fujiwara M. Cannabidiol prevents a postischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacol 2008;55:1280-1286.
17. Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M. Repeated treatment with cannabidiol but not Delta9-Tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacol 2007;52:1079-1087.
18. Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, Fujiwara M. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptordependent mechanism. Stroke 2005;36:1077-1082.
19. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Irie K, Fujioka M, Orito K, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M. Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidaseinhibiting mechanism. J Neurochem 2007;102:1488-1496.
20. Jarai Z, Wagner JA, Varga KR, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G. Cannabinoidinduced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999;96:14136-14141.
21. Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK, Martin BR, Bukoski RD, Kunos G. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 2003;63:699-705.
22. OSullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA. Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 2009;612:61-68.
23. Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, OSullivan SE. Endocannabinoids modulate human blood-brain barrier permeability in vitro. Br J Pharmacol 2015. doi:10.1111/bph.13106.
24. Spinsanti G, Zannolli R, Panti C, Ceccarelli I, Marsili L, Bachiocco V, Frati F, Aloisi AM. Quantitative real-Time PCR detection of TRPV1-4 gene expression in human leukocytes from healthy and hyposensitive subjects. Mol Pain 2008;4:51.
25. Reynders V, Loitsch S, Steinhauer C, Wagner T, Steinhilber D, Bargon J. Peroxisome proliferator-Activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes. Resp Res 2006;7:104.
26. Cencioni MT, Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 2010;5:e8688.
27. Luo D, Zhang YW, Peng WJ, Peng J, Chen QQ, Li D, Deng HW, Li YJ. Transient receptor potential vanilloid 1-mediated expression and secretion of endothelial cell-derived calcitonin gene-related peptide. Regul Peptides 2008;150:66-72.
28. Dong YL, Fang L, Kondapaka S, Gangula PR, Wimalawansa SJ, Yallampalli C. Involvement of calcitonin gene-related peptide in the modulation of human myometrial contractility during pregnancy. J Clin Invest 1999;104:559-565.
29. Begg M, Mo FM, Offertaler L, Batkai S, Pacher P, Razdan RK, Lovinger DM, Kunos G. G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. J Biol Chem 2003;278:46188-46194.
30. Fantozzi I, Zhang S, Platoshyn O, Remillard CV, Cowling RT, Yuan JXJ. Hypoxia increases AP-1 binding activity by enhancing capacitative Ca2+ entry in human pulmonary artery endothelial cells. Am J Physiol 2003;285:L1233-L1245.
31. Wang J, Okamoto Y, Tsuboi K, Ueda N. The stimulatory effect of phosphatidylethanolamine on N-Acylphosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD). Neuropharmacol 2008;54:8-15.
32. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an endogenous cannabimimetic molecule, 2-Arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-Arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res 1998;243:838-843.
33. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, Csiszar A, Ungvari Z, Mackie K, Chatterjee S, Pacher P. CB2-receptor stimulation attenuates TNF-Alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007; 293:H2210-H2218.
34. Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K, Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-Alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 2008;153:347-357.
35. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000;346(Pt 3):835-840.
36. Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996;278: 989-999.
37. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-852.
38. Stanley C, Manning G, OSullivan S. Cannabinoid induced vasorelaxation of human mesenteric arteries. Proceeding of the British Pharmacolgoical Scoiety Meeting 2010. http://bps.conference-services.net/resources/344/2336/pdf/BPSWINTER10-0158.pdf.
39. Stanley CP, OSullivan SE. Cyclooxygenase metabolism mediates vasorelaxation to 2-Arachidonoylglycerol (2-AG) in human mesenteric arteries. Pharmacol Res 2014;81: 74-82.
40. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, Moore LC. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997;100:1538-1546.
41. De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163: 1479-1494.
42. Yamada T, Ueda T, Shibata Y, Ikegami Y, Saito M, Ishida Y, Ugawa S, Kohri K, Shimada S. TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer. Urology 2010;76:509 e501-507.
43. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004;143:247-250.
44. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 2007;556:75-83.
45. Zygmunt PM, Andersson DA, Hogestatt ED. Delta 9-Tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 2002;22:4720-4727.
46. Edvinsson L, Ahnstedt H, Larsen R, Sheykhzade M. Differential localization and characterization of functional calcitonin gene-related peptide receptors in human subcutaneous arteries. Acta Physiol 2014;210:811-822.
47. OSullivan SE, Kendall DA, Randall MD. Further characterization of the time-dependent vascular effects of D29 tetrahydrocannabinol. J Pharmacol Exp Ther 2006;317:428-438.
48. OSullivan SE, Kendall DA, Randall MD. The effects of Delta9-Tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol 2005;145:514-526.
49. Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, Mechoulam R, Pertwee RG, Parker LA. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 2012;165:2620-2634.
50. Campos AC, Guimaraes FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacol 2008;199:223-230.
51. McCollum L, Howlett AC, Mukhopadhyay S. Anandamide-mediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther 2007;321:930-937.
52. Mo FM, Offertaler L, Kunos G. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol 2004;489:21-27.
53. Mukhopadhyay P, Rajesh M, Horvath B, Batkai S, Park O, Tanchian G, Gao RY, Patel V, Wink DA, Liaudet L, Hasko G, Mechoulam R, Pacher P. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Rad Biol Med 2011;50: 1368-1381.
54. Dando I, Donadelli M, Costanzo C, Dalla Pozza E, Dalessandro A, Zolla L, Palmieri M. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. Cell Death Dis 2013;4:e664.
55. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, Egia A, Vazquez P, Blazquez C, Torres S, Garcia S, Nowak J, Fimia GM, Piacentini M, Cecconi F, Pandolfi PP, Gonzalez-Feria L, Iovanna JL, Guzman M, Boya P, Velasco G. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 2009;119:1359-1372.
56. Yang X, Meyer K, Friedl A. STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis. J Biol Chem 2013;288:21184-21196.
57. Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D, Cinquina V, Valenti M, Vicentini LM, Noonan DM, Albini A, Parolaro D. Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol 2012;167:1218-1231.
58. Novella S, Dantas AP, Segarra G, Medina P, Hermenegildo C. Vascular aging in women: is estrogen the fountain of youth? Front Physiol 2012;3:165.
59. Onaivi ES, Chaudhuri G, Abaci AS, Parker M, Manier DH, Martin PR, Hubbard JR. Expression of cannabinoid receptors and their gene transcripts in human blood cells. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:1063-1077.
60. Lobato NS, Filgueira FP, Prakash R, Giachini FR, Ergul A, Carvalho MH, Webb RC, Tostes RC, Fortes ZB. Reduced endothelium-dependent relaxation to anandamide in mesenteric arteries from young obese Zucker rats. PLoS One 2013;8:e63449.
61. Steffens S, Pacher P. Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. Br J Pharmacol 2012;167:313-323.
62. Guarini G, Ohanyan VA, Kmetz JG, DelloStritto DJ, Thoppil RJ, Thodeti CK, Meszaros JG, Damron DS, Bratz IN. Disruption of TRPV1-mediated coupling of coronary blood flow to cardiac metabolism in diabetic mice: role of nitric oxide and BK channels. Am J Physiol Heart Circ Physiol 2012;303:H216-H223.
63. Picazo-Juarez G, Romero-Suarez S, Nieto-Posadas A, Llorente I, Jara-Oseguera A, Briggs M, McIntosh TJ, Simon SA, Ladro n-de-Guevara E, Islas LD, Rosenbaum T. Identification of a binding motif in the S5 helix that confers cholesterol sensitivity to the TRPV1 ion channel. J Biol Chem. 2011;286:24966-24976.